Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central anxious technique, conolidine modulates alternate molecular targets. A Science Innovations analyze found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://alfredn875ptw8.blogmazing.com/profile